Toll-like receptors in innate immunity and infectious diseases

Frontiers of Medicine in China

Volumn 4, Issue 4, 2010, Pages 385-393

  Wu, Min Hao ^a,b   Zhang, Ping ^a,b   Huang, Xi ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

infectious disease; inflammation; innate immunity; Toll like receptors

Indexed keywords

TOLL LIKE RECEPTOR;

CLASSIFICATION; COMMUNICABLE DISEASE; GENE EXPRESSION; GENETICS; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; KERATITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; SIGNAL TRANSDUCTION; TUBERCULOSIS;

COMMUNICABLE DISEASES; GENE EXPRESSION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, INNATE; KERATITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUBERCULOSIS;

EID: 78650694286     PISSN: 16737342     EISSN: 16737458     Source Type: Journal    
DOI: 10.1007/s11684-010-0600-x     Document Type: Review

References (96)

1. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med, 2000, 343(5): 338-344.
2. Janeway C A Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol, 2002, 20: 197-216.
3. Medzhitov R, Janeway C A Jr. How does the immune system distinguish self from nonself? Semin Immunol, 2000, 12(3): 185-188, discussion 257-344.
4. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol, 2007, 3(7): 382-390.
5. Fraser I P, Koziel H, Ezekowitz R A. The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol, 1998, 10(5): 363-372.
6. Bowdish D M, Gordon S. Conserved domains of the class A scavenger receptors: evolution and function. Immunol Rev, 2009, 227(1): 19-31.
7. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature, 2004, 430(6996): 257-263.
8. Bianchi M E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol, 2007, 81(1): 1-5.
9. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol, 2004, 4(7): 499-511.
10. Wheeler D S, Chase M A, Senft A P, Poynter S E, Wong H R, Page K. Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4. Respir Res, 2009, 10: 31.
11. Halayko A J, Ghavami S. S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? Can J Physiol Pharmacol, 2009, 87(10): 743-755.
12. Jin M S, Lee J O. Structures of the toll-like receptor family and its ligand complexes. Immunity, 2008, 29(2): 182-191.
13. O'Neill L A, Bowie A G. The family of five: TIR-domaincontaining adaptors in Toll-like receptor signalling. Nat Rev Immunol, 2007, 7(5): 353-364.
14. Dowling D, Hamilton C M, O'Neill S M. A comparative analysis of cytokine responses, cell surface marker expression and MAPKs in DCs matured with LPS compared with a panel of TLR ligands. Cytokine, 2008, 41(3): 254-262.
15. Lien E, Chow J C, Hawkins L D, McGuinness P D, Miyake K, Espevik T, Gusovsky F, Golenbock D T. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/tolllike receptor 4 signaling pathway. J Biol Chem, 2001, 276(3): 1873-1880.
16. Wang D, Lou J, Ouyang C, Chen W, Liu Y, Liu X, Cao X, Wang J, Lu L. Ras-related protein Rab10 facilitates TLR4 signaling by promoting replenishment of TLR4 onto the plasma membrane. Proc Natl Acad Sci U S A, 2010, 107(31): 13806-13811.
17. Lang L L, Wang L, Liu L. Exogenous MD-2 Confers Lipopolysaccharide Responsiveness to Human Corneal Epithelial Cells with Intracellular Expression of TLR4 and CD14. Inflammation, 2010 Aug 11. doi: 10: 1007/s10753-010-9244-x.
18. Aliprantis A O, Yang R B, Mark M R, Suggett S, Devaux B, Radolf J D, Klimpel G R, Godowski P, Zychlinsky A. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science, 1999, 285(5428): 736-739.
19. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning C J. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem, 1999, 274(25): 17406-17409.
20. Takeda K, Takeuchi O, Akira S. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res, 2002, 8(6): 459-463.
21. Ozinsky A, Underhill D M, Fontenot J D, Hajjar A M, Smith K D, Wilson C B, Schroeder L, Aderem A. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A, 2000, 97(25): 13766-13771.
22. Nakao Y, Funami K, Kikkawa S, Taniguchi M, Nishiguchi M, Fukumori Y, Seya T, Matsumoto M. Surface-expressed TLR6 participates in the recognition of diacylated lipopeptide and peptidoglycan in human cells. J Immunol, 2005, 174(3): 1566-1573.
23. Henneke P, Morath S, Uematsu S, Weichert S, Pfitzenmaier M, Takeuchi O, Müller A, Poyart C, Akira S, Berner R, Teti G, Geyer A, Hartung T, Trieu-Cuot P, Kasper D L, Golenbock D T. Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J Immunol, 2005, 174(10): 6449-6455.
24. von Aulock S, Morath S, Hareng L, Knapp S, van Kessel K P, van Strijp J A, Hartung T. Lipoteichoic acid from Staphylococcus aureus is a potent stimulus for neutrophil recruitment. Immunobiology, 2003, 208(4): 413-422.
25. Shimizu T, Kida Y, Kuwano K. A triacylated lipoprotein from Mycoplasma genitalium activates NF-kappaB through Toll-like receptor 1 (TLR1) and TLR2. Infect Immun, 2008, 76(8): 3672-3678.
26. Shimizu T, Kida Y, Kuwano K. Triacylated lipoproteins derived from Mycoplasma pneumoniae activate nuclear factor-kappaB through toll-like receptors 1 and 2. Immunology, 2007, 121(4): 473-483.
27. Hayashi F, Smith K D, Ozinsky A, Hawn T R, Yi E C, Goodlett D R, Eng J K, Akira S, Underhill D M, Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature, 2001, 410(6832): 1099-1103.
28. Yarovinsky F, Zhang D, Andersen J F, Bannenberg G L, Serhan C N, Hayden M S, Hieny S, Sutterwala F S, Flavell R A, Ghosh S, Sher A. TLR11 activation of dendritic cells by a protozoan profilinlike protein. Science, 2005, 308(5728): 1626-1629.
29. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell R A, Ghosh S. A toll-like receptor that prevents infection by uropathogenic bacteria. Science, 2004, 303(5663): 1522-1526.
30. Liu L, Botos I, Wang Y, Leonard J N, Shiloach J, Segal DM, Davies D R. Structural basis of toll-like receptor 3 signaling with doublestranded RNA. Science, 2008, 320(5874): 379-381.
31. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S A. A Tolllike receptor recognizes bacterial DNA. Nature, 2000, 408(6813): 740-745.
32. Gantier M P, Tong S, Behlke M A, Xu D, Phipps S, Foster P S, Williams B R. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J Immunol, 2008, 180(4): 2117-2124.
33. Hammadi A, Billard C, Faussat AM, Kolb J P. Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation. Nitric Oxide, 2008, 19(2): 138-145.
34. Pivarcsi A, Nagy I, Koreck A, Kis K, Kenderessy-Szabo A, Szell M, Dobozy A, Kemeny L. Microbial compounds induce the expression of pro-inflammatory cytokines, chemokines and human betadefensin-2 in vaginal epithelial cells. Microbes Infect, 2005, 7(9-10): 1117-1127.
35. Becker M N, Diamond G, Verghese M W, Randell S H. CD14-dependent lipopolysaccharide-induced beta-defensin-2 expression in human tracheobronchial epithelium. J Biol Chem, 2000, 275(38): 29731-29736.
36. Alter G, Suscovich T J, Teigen N, Meier A, Streeck H, Brander C, Altfeld M. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol, 2007, 178(12): 7658-7666.
37. Wang J, Shao Y, Bennett T A, Shankar R A, Wightman P D, Reddy L G. The functional effects of physical interactions among Toll-like receptors 7, 8, and 9. J Biol Chem, 2006, 281(49): 37427-37434.
38. Yarovinsky F, Sher A. Toll-like receptor recognition of Toxoplasma gondii. Int J Parasitol, 2006, 36(3): 255-259.
39. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, Guiet C, Brière F, Vlach J, Lebecque S, Trinchieri G, Bates E E. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol, 2005, 174(5): 2942-2950.
40. Guan Y, Ranoa D R, Jiang S, Mutha S K, Li X, Baudry J, Tapping R I. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J Immunol, 2010, 184(9): 5094-5103.
41. Schnare M, Barton G M, Holt A C, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol, 2001, 2(10): 947-950.
42. Vora P, Youdim A, Thomas L S, Fukata M, Tesfay S Y, Lukasek K, Michelsen K S, Wada A, Hirayama T, Arditi M, Abreu M T. Betadefensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol, 2004, 173(9): 5398-5405.
43. Wu M, McClellan S A, Barrett R P, Hazlett L D. Beta-defensin-2 promotes resistance against infection with P. aeruginosa. J Immunol, 2009, 182(3): 1609-1616.
44. Wu M, McClellan S A, Barrett R P, Zhang Y, Hazlett L D. Betadefensins 2 and 3 together promote resistance to Pseudomonas aeruginosa keratitis. J Immunol, 2009, 183(12): 8054-8060.
45. Chen X M, O'Hara S P, Nelson J B, Splinter P L, Small A J, Tietz P S, Limper A H, LaRusso N F. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB. J Immunol, 2005, 175(11): 7447-7456.
46. Kumar A, Yin J, Zhang J, Yu F S. Modulation of corneal epithelial innate immune response to pseudomonas infection by flagellin pretreatment. Invest Ophthalmol Vis Sci, 2007, 48(10): 4664-4670.
47. Funderburg N, Lederman M M, Feng Z, Drage M G, Jadlowsky J, Harding C V, Weinberg A, Sieg S F. Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci U S A, 2007, 104(47): 18631-18635.
48. Biragyn A, Ruffini P A, Leifer C A, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa A K, Farber J M, Segal D M, Oppenheim J J, Kwak L W. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science, 2002, 298(5595): 1025-1029.
49. Davila S, Hibberd M L, Hari Dass R, Wong H E, Sahiratmadja E, Bonnard C, Alisjahbana B, Szeszko J S, Balabanova Y, Drobniewski F, van Crevel R, van de Vosse E, Nejentsev S, Ottenhoff T H, Seielstad M. Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. PLoS Genet, 2008, 4(10): e1000218.
50. Ma X, Liu Y, Gowen B B, Graviss E A, Clark A G, Musser J M. Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One, 2007, 2(12): e1318.
51. Velez D R, Wejse C, Stryjewski M E, Abbate E, Hulme W F, Myers J L, Estevan R, Patillo S G, Olesen R, Tacconelli A, Sirugo G, Gilbert J R, Hamilton C D, Scott WK. Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. Hum Genet, 2010, 127(1): 65-73.
52. Abel B, Thieblemont N, Quesniaux V J, Brown N, Mpagi J, Miyake K, Bihl F, Ryffel B. Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J Immunol, 2002, 169(6): 3155-3162.
53. Yang C S, Shin DM, Lee HM, Son JW, Lee S J, Akira S, Gougerot-Pocidalo M A, El-Benna J, Ichijo H, Jo E K. ASK1-p38 MAPKp47phox activation is essential for inflammatory responses during tuberculosis via TLR2-ROS signalling. Cell Microbiol, 2008, 10(3): 741-754.
54. Castiblanco J, Varela D C, Castaño-Rodríguez N, Rojas-Villarraga A, Hincapié M E, Anaya J M. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol, 2008, 8(5): 541-544.
55. Dissanayeke S R, Levin S, Pienaar S, Wood K, Eley B, Beatty D, Henderson H, Anderson S, Levin M. Polymorphic variation in TIRAP is not associated with susceptibility to childhood TB but may determine susceptibility to TBM in some ethnic groups. PLoS One, 2009, 4(8): e6698.
56. Doherty T M, Arditi M T B. TB, or not TB: that is the question - does TLR signaling hold the answer? J Clin Invest, 2004, 114(12): 1699-1703.
57. Hazlett L D. Corneal response to Pseudomonas aeruginosa infection. Prog Retin Eye Res, 2004, 23(1): 1-30.
58. Jin X, Lin Z, Xie X. The delayed response of Toll-like receptors may relate to Pseudomonas aeruginosa keratitis exacerbating rapidly at the early stages of infection. Eur J Clin Microbiol Infect Dis, 2010, 29(2): 231-238.
59. Gao N, Kumar A, Jyot J, Yu F S. Flagellin-induced corneal antimicrobial peptide production and wound repair involve a novel NF-kappaB-independent and EGFR-dependent pathway. PLoS One, 2010, 5(2): e9351.
60. Hazlett L D, McClellan S, Kwon B, Barrett R. Increased severity of Pseudomonas aeruginosa corneal infection in strains of mice designated as Th1 versus Th2 responsive. Invest Ophthalmol Vis Sci, 2000, 41(3): 805-810.
61. Huang X, Barrett R P, McClellan S A, Hazlett L D. Silencing Tolllike receptor-9 in Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci, 2005, 46(11): 4209-4216.
62. Huang X, Du W, McClellan S A, Barrett R P, Hazlett L D. TLR4 is required for host resistance in Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci, 2006, 47(11): 4910-4916.
63. Huang X, Hazlett L D, Du W, Barrett R P. SIGIRR promotes resistance against Pseudomonas aeruginosa keratitis by downregulating type-1 immunity and IL-1R1 and TLR4 signaling. J Immunol, 2006, 177(1): 548-556.
64. Huang X, Du W, Barrett R P, Hazlett L D. ST2 is essential for Th2 responsiveness and resistance to pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci, 2007, 48(10): 4626-4633.
65. Lok A S, McMahon B J, O. Chronic hepatitis B. Hepatology, 2001, 34(6): 1225-1241.
66. Rantala M, van de Laar M J. Surveillance and epidemiology of hepatitis B and C in Europe-a review. Euro Surveill, 2008, 13(21): 13.
67. Brown R A, Gralewski J H, Eid A J, Knoll B M, Finberg R W, Razonable R R. R753Q single-nucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and nonstructural 3 proteins. Transplantation, 2010, 89(7): 811-815.
68. Li Y, Chang M, Abar O, Garcia V, Rowland C, Catanese J, Ross D, Broder S, Shiffman M, Cheung R, Wright T, Friedman S L, Sninsky J. Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol, 2009, 51(4): 750-757.
69. Askar E, Bregadze R, Mertens J, Schweyer S, Rosenberger A, Ramadori G, Mihm S. TLR3 gene polymorphisms and liver disease manifestations in chronic hepatitis C. J Med Virol, 2009, 81(7): 1204-1211.
70. Schott E, Witt H, Neumann K, Taube S, Oh D Y, Schreier E, Vierich S, Puhl G, Bergk A, Halangk J, Weich V, Wiedenmann B, Berg T A. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol, 2007, 47(2): 203-211.
71. Zhou J, Huang Y, Tian D, Xu D, Chen M, Wu H. Expression of tolllike receptor 9 in peripheral blood mononuclear cells from patients with different hepatitis B and C viral loads. J Huazhong Univ Sci Technolog Med Sci, 2009, 29(3): 313-317.
72. Wang J P, Zhang Y, Wei X, Li J, Nan X P, Yu H T, Li Y, Wang P Z, Bai X F. Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS, 2010, 118(4): 261-270.
73. Lester R T, Yao X D, Ball T B, McKinnon L R, Kaul R, Wachihi C, Jaoko W, Plummer F A, Rosenthal K L. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS, 2008, 22(6): 685-694.
74. Ahmed N, Hayashi T, Hasegawa A, Furukawa H, Okamura N, Chida T, Masuda T, Kannagi M. Suppression of human immunodeficiency virus type-1 (HIV-1) replication in macrophages by commensal bacteria preferentially stimulating toll-like receptor 4. J Gen Virol, 2010, 91(Pt 11): 2804-2813.
75. Pine S O, McElrath M J, Bochud P Y. Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS, 2009, 23(18): 2387-2395.
76. Báfica A, Scanga C A, Schito M, Chaussabel D, Sher A. Influence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors. J Immunol, 2004, 172(12): 7229-7234.
77. Bochud P Y, Hersberger M, Taffé P, Bochud M, Stein C M, Rodrigues S D, Calandra T, Francioli P, Telenti A, Speck R F, Aderem A, O. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS, 2007, 21(4): 441-446.
78. Soriano-Sarabia N, Vallejo A, Ramírez-Lorca R, Rodríguez Mdel M, Salinas A, Pulido I, Sáez M E, Leal M. Influence of the Toll-like receptor 9 1635A/G polymorphism on the CD4 count, HIV viral load, and clinical progression. J Acquir Immune Defic Syndr, 2008, 49(2): 128-135.
79. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, Si-Tahar M. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem, 2005, 280(7): 5571-5580.
80. Marshall-Clarke S, Tasker L, Buchatska O, Downes J, Pennock J, Wharton S, Borrow P, Wiseman D Z. Influenza H2 haemagglutinin activates B cells via a MyD88-dependent pathway. Eur J Immunol, 2006, 36(1): 95-106.
81. Wang J P, Bowen G N, Padden C, Cerny A, Finberg R W, Newburger P E, Kurt-Jones E A. Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood, 2008, 112(5): 2028-2034.
82. Pierik M, Joossens S, van Steen K, van Schuerbeek N, Vlietinck R, Rutgeerts P, Vermeire S. Toll-like receptor-1, -2, and-6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis, 2006, 12(1): 1-8.
83. Török H P, Glas J, Endres I, Tonenchi L, Teshome M Y, Wetzke M, Klein W, Lohse P, Ochsenkühn T, Folwaczny M, Göke B, Folwaczny C, Müller-Myhsok B, Brand S. Epistasis between Tolllike receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol, 2009, 104(7): 1723-1733.
84. Franchimont D, Vermeire S, El Housni H, Pierik M, van Steen K, Gustot T, Quertinmont E, Abramowicz M, van Gossum A, Devière J, Rutgeerts P. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut, 2004, 53(7): 987-992.
85. Gewirtz A T, Vijay-Kumar M, Brant S R, Duerr R H, Nicolae D L, Cho J H. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol, 2006, 290(6): G1157-G1163.
86. Leoratti F M, Farias L, Alves F P, Suarez-Mútis M C, Coura J R, Kalil J, Camargo E P, Moraes S L, Ramasawmy R. Variants in the toll-like receptor signaling pathway and clinical outcomes of malaria. J Infect Dis, 2008, 198(5): 772-780.
87. Hamann L, Bedu-Addo G, Eggelte T A, Schumann R R, Mockenhaupt F P. The toll-like receptor 1 variant S248N influences placental malaria. Infect Genet Evol, 2010, 10(6): 785-789.
88. Basu M, Maji A K, Chakraborty A, Banerjee R, Mullick S, Saha P, Das S, Kanjilal S D, Sengupta S. Genetic association of Toll-likereceptor 4 and tumor necrosis factor-alpha polymorphisms with Plasmodium falciparum blood infection levels. Infect Genet Evol, 2010, 10(5): 686-696.
89. Chen J, Xu W, Zhou T, Ding Y, Duan J, Huang F. Inhibitory role of toll-like receptors agonists in Plasmodium yoelii liver stage development. Parasite Immunol, 2009, 31(8): 466-473.
90. Greene J A, Moormann AM, Vulule J, Bockarie MJ, Zimmerman P A, Kazura JW. Toll-like receptor polymorphisms in malaria-endemic populations. Malar J, 2009, 8: 50.
91. Crompton P D, Mircetic M, Weiss G, Baughman A, Huang C Y, Topham D J, Treanor J J, Sanz I, Lee F E, Durbin A P, Miura K, Narum D L, Ellis R D, Malkin E, Mullen G E, Miller L H, Martin L B, Pierce S K. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol, 2009, 182(5): 3318-3326.
92. Sam-Agudu N A, Greene J A, Opoka R O, Kazura JW, Boivin M J, Zimmerman P A, Riedesel M A, Bergemann T L, Schimmenti L A, John C C. TLR9 polymorphisms are associated with altered IFNgamma levels in children with cerebral malaria. Am J Trop Med Hyg, 2010, 82(4): 548-555.
93. Wong S H, Gochhait S, Malhotra D, Pettersson F H, Teo Y Y, Khor C C, Rautanen A, Chapman S J, Mills T C, Srivastava A, Rudko A, Freidin M B, Puzyrev V P, Ali S, Aggarwal S, Chopra R, Reddy B S, Garg V K, Roy S, Meisner S, Hazra S K, Saha B, Floyd S, Keating B J, Kim C, Fairfax B P, Knight J C, Hill P C, Adegbola R A, Hakonarson H, Fine P E, Pitchappan R M, Bamezai R N, Hill A V, Vannberg F O. Leprosy and the adaptation of human toll-like receptor 1. PLoS Pathog, 2010, 6: e1000979.
94. Schuring R P, Hamann L, Faber W R, Pahan D, Richardus J H, Schumann R R, Oskam L. Polymorphism N248S in the human Tolllike receptor 1 gene is related to leprosy and leprosy reactions. J Infect Dis, 2009, 199(12): 1816-1819.
95. Krutzik S R, Ochoa MT, Sieling P A, Uematsu S, Ng YW, Legaspi A, Liu P T, Cole S T, Godowski P J, Maeda Y, Sarno E N, Norgard M V, Brennan P J, Akira S, Rea T H, Modlin R L. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med, 2003, 9(5): 525-532.
96. Johnson C M, Lyle E A, Omueti K O, Stepensky V A, Yegin O, Alpsoy E, Hamann L, Schumann R R, Tapping R I. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol, 2007, 178(12): 7520-7524.